Meeting
2024 ASCO Annual Meeting
Serial circulating tumor DNA monitoring for predicting treatment response and prognosis in patients with pancreatic cancer.
Authors
Jongchan Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea
Jongchan Lee , Jinwoo Ahn , Kwangrok Jung , Jong-chan Lee , Yuna Youn , Jin-Hyeok Hwang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer - Advanced/Metastatic Disease
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 4154)
DOI
10.1200/JCO.2024.42.16_suppl.4154
Abstract #
4154
Poster Bd #
134
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multicenter observational study of nanoliposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Final retrospective results.
First Author: Takashi Imajima
First Author: Jacqueline Shaw
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA-based molecular residual disease detection and recurrence monitoring in patients with advanced or metastatic anal squamous cell carcinoma.
First Author: Georges Azzi
Poster
2017 Gastrointestinal Cancers Symposium
![Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.](https://d201v5jt9ylckg.cloudfront.net/195/11777/139522/139522_poster_pv.jpg)
Phase 1b dose-escalation and cohort-expansion study of the safety, tolerability, and efficacy of a novel transforming growth factor-β receptor I kinase inhibitor (galunisertib [G]) administered in combination with the anti-PD-L1 antibody (durvalumab [D]) in recurrent or refractory metastatic pancreatic cancer.
First Author: Davide Melisi